FDA approves 1st 2-drug HIV treatment

Ella Jeffries / beckershospitalreview - The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients with no history of virologic treatment failure and no k…

AI Summary: The FDA has approved Merck’s once‑daily two‑drug antiretroviral regimen, marking a notable market entrant poised to compete with established single‑pill therapies. Regulators cleared the novel combination on efficacy and safety data, setting up potential shifts in prescribing, pricing and competition — and giving Gilead something new to grumble about.

340B drug discounts are drifting from patients to profit, and reform is now on the table

medicalxpress - The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking behaviors, says the American College of Physicians (ACP). In a new policy, "Reforming 340B to Promote Program Integrity and Better Serv…

AI Summary: The 340B drug-discount program is under renewed scrutiny after analyses and advocacy groups argue discounts intended to help patients are instead boosting institutional margins. Hospitals, provider groups and the AHA are contesting HRSA proposals and court rulings, sparking policy debates and potential regulatory fixes to curb markups and steer savings back to vulnerable patients.

CMS to require states to audit Medicaid providers

Kristin Kuchno / beckershospitalreview - CMS Administrator Mehmet Oz, MD, said his administration will require all states to audit healthcare providers to address alleged Medicaid fraud, Politico reported April 21. Dr. Oz unveiled the plan at Politico’s Health Care Summit. Beginning this week, C…

AI Summary: CMS is requiring states to audit Medicaid providers as part of a new oversight initiative aimed at tightening program integrity and provider revalidation. The policy has sparked high‑level calls for nationwide reviews and a proposed 50‑state audit effort, signaling heightened federal scrutiny and potential changes to enrollment, billing and provider eligibility processes.

Long-term Use of Immunotherapy May Be Safe for Patients With Alveolar Soft Part Sarcoma

Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …

AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.

Improving oral care more than halves hospital-acquired pneumonia risk, major trial finds

medicalxpress - A landmark trial presented at ESCMID Global 2026 shows that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) by 60%.

AI Summary: A major randomized trial found that simple improvements in oral care—regular toothbrushing and mouth hygiene—cut hospital‑acquired pneumonia risk by over half in hospitalized patients. The low‑cost intervention reduced respiratory complications and antibiotic use, suggesting wards could prevent serious infections with a toothbrush rather than another headline‑seeking drug.

E-bike and scooter crashes driving more brain injuries

medicalxpress - The growing use of electric bikes and scooters has caused a surge in brain and spine injuries among urban riders and pedestrians, a new study shows. Led by NYU Langone Health researchers, the study found that these injuries now account for nearly 7% of tr…

AI Summary: A new analysis links the rise of e‑bikes and scooters to a measurable increase in traumatic brain injuries and trauma admissions, accounting for roughly 7% of related cases in the examined data. Researchers urge better helmet uptake, infrastructure changes and policy action to curb preventable head injuries before cities regret their micro‑mobility love affair.

CDC: Proportion of extensively drug-resistant Shigella isolates increasing

medicalxpress - The proportion of extensively drug-resistant (XDR) Shigella isolates in the United States increased from 2011–2015 to 2023, according to research published in the April 9 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality…

AI Summary: Federal health officials report a worrying uptick in extensively drug‑resistant Shigella strains, complicating treatment and raising the risk of harder‑to‑control outbreaks. The data underscore the need for enhanced surveillance, hygiene measures, antibiotic stewardship and rapid public‑health responses as standard antibiotics lose reliability. Try not to spread it—literally.

Three gene therapy pioneers just won the Breakthrough Prize. This is their story

Ryan Cross / endpoints - A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably one of the most prominent recognitions yet for the field ...

AI Summary: Three gene‑therapy researchers received the Breakthrough Prize in recognition of foundational work that enabled the first CRISPR-based sickle cell therapy. The award highlights decades of basic and translational research that turned genome editing from lab curiosity into a tangible clinical remedy, with winners sharing a multimillion‑dollar prize and public acclaim.

First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape

oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]

AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.

Growing liver tissue directly in the body could ease donor organ shortage

medicalxpress - In patients developing end-stage liver disease, the damage has become too severe for the liver's normally extraordinary regenerative capacity to repair or compensate for it. Once this "point of no return" has been reached, the only option is an organ tran…

AI Summary: Scientists report a technique to grow liver tissue directly inside the body as a potential solution to donor organ shortages, demonstrating functional hepatic tissue formation in preclinical or early clinical models. The promising results have been followed by an editorial expression of concern over methodology and data, prompting calls for independent validation before wider clinical use.

FDA updates mifepristone safety study status

Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…

AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.

First-in-human trial primes immune system to accept donor livers

medicalxpress - UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique "immune priming" therapy.

AI Summary: A first‑in‑human study reports a novel immune‑priming approach that enabled three liver transplant recipients to stop standard lifelong immunosuppression. The intervention appears to induce tolerance to donor tissue, reducing dependence on anti‑rejection drugs and their toxic side effects, offering a potential shift in transplant management if larger trials confirm these early results.

'I'm not being listened to' - new health plan launched as women say they are still ignored

bbc - New plans to improve healthcare for women and girls have been set out, but will they change anything?

AI Summary: Health officials unveiled a new women's health plan, but many women say the rollout feels performative and that their concerns remain unheard. Patient advocates warn the initiative risks repeating past mistakes unless it embeds lived experience, transparent accountability and genuine co-design—otherwise it's policy theater with a glossy brochure.

Florida surgeon charged with manslaughter after removing wrong organ

Mariah Taylor / beckershospitalreview - Thomas Shaknovsky, MD, a Florida surgeon, was charged April 13 with second-degree manslaughter in connection with the death of a 70-year-old man during surgery. The Alabama man was vacationing in Florida when he experienced severe pain on his left side, T…

AI Summary: A Florida surgeon has been criminally charged with manslaughter after allegedly removing the wrong organ during an operation that resulted in a patient’s death. Prosecutors say the error was catastrophic, triggering an investigation and renewed scrutiny of surgical safety protocols, oversight practices, and how a single clinical mistake escalates into a criminal case.